On September 1, Medtronic PLC rose 4.74% in regular trading, trading at approximately $93.23 per share, with turnover of $2.12 billion. The surge was driven by the company's FY2027 first-quarter earnings release before market open, which delivered a comprehensive beat on both top and bottom lines, accompanied by an upward revision of full-year guidance.

Medtronic reported Q1 revenue of $9.76 billion, up 13.8% year-over-year, exceeding consensus estimates by approximately $220 million. Non-GAAP diluted EPS came in at $1.45, beating the $1.39 estimate by $0.06, representing a 15.1% year-over-year increase. The cardiovascular segment was the standout performer, surging 18.9% year-over-year, fueled by strong demand for devices used in complex cardiac procedures. An additional operating week contributed roughly $570 million in revenue.

Management raised full-year organic revenue growth guidance to 7.25%–7.75%, up 50 basis points from prior expectations, and lifted the adjusted EPS range to $5.94–$6.00, with the new floor exceeding the Wall Street consensus of $5.95. Concurrently, Medtronic announced a $700 million strategic partnership with Cornerstone Robotics to accelerate global robotic-assisted surgery adoption, and an up to $80 million investment in Pi-Cardia for its FDA-approved ShortCut transcatheter device.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)